- Advanced search
- Immuno Portal
- Malaria Portal
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Originally approved to abrogate renal allograft rejection. Zenapax® was withdrawn from use, at the request of the marketing authorisation holder (Roche) for commercial reasons.
A Phase II clinical trial NCT01468311 investigating the use of radio-labelled daclizumab as part of the immunosuppressive conditioning regimen in preparation for stem cell transplant in Hodgkin's lymphoma patients was suspended before completion.
Daclizumab beta (BIIB019, produced in a high yield process) is being evaluated in Phase III clinical trial for relapsing-remitting multiple sclerosis (MS). Click here to view these Phase III trials at ClinicalTrials.gov. Pharmacokinetics of daclizumab beta are published in . In May 2016, the US FDA approved the once-monthly daclizumab injection, Zinbryta® (which contains daclizumab beta) for the treatment of patients with relapsing forms of MS, but is only to be used for patients who have had an inadequate response to two or more MS drugs.
|Mechanism Of Action and Pharmacodynamic Effects|
|Abrogates the critical cellular immune response involved in allograft rejection by binding the CD25 subunit of the IL-2 receptor complex, preventing IL-2 binding and thereby inhibiting IL-2-mediated activation of lymphocytes.
In relapsing-remitting MS aberrant CD25 expression and abnormal activation of immune cells underlies the pathological demyelination of nerves. Daclizumab beta binding to CD25 is predicted to normalize immune cell activity, slowing the progress of the disease and reducing relapses .